---
annotation-target: blood.2022018052.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-15T02:12:53.629Z","updated":"2022-09-15T02:12:53.629Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":3645,"end":3710},{"type":"TextQuoteSelector","exact":"Clonal Hematopoiesis of Indeterminate Potential and Risk of Death","prefix":"t on 14 September 2022  1TITLE: ","suffix":" from COVID-19  Peter G. Miller1"}]}]}
>```
>%%
>*%%PREFIX%%t on 14 September 2022  1TITLE:%%HIGHLIGHT%% ==Clonal Hematopoiesis of Indeterminate Potential and Risk of Death== %%POSTFIX%%from COVID-19  Peter G. Miller1*
>%%LINK%%[[#^95u9ogxieiv|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^95u9ogxieiv


>%%
>```annotation-json
>{"created":"2022-09-15T02:13:36.829Z","updated":"2022-09-15T02:13:36.829Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":5999,"end":6651},{"type":"TextQuoteSelector","exact":"Clonal hematopoiesis of indeterminate potential (CHIP) is a subtype of clonal hematopoiesis found in individuals without a hematologic malignancy in which a somatic pathogenic mutation in a gene mutated in myeloid neoplasia is present in at least 2% of the sequenced blood DNA (termed variant allele fraction, or VAF).1,2 CHIP is associated with increased mortality and risk of adverse outcomes including cardiovascular and pulmonary disease (COPD).3-5 These associations, which are largely driven by CHIP clones with VAF greater than 0.1, are thought to arise from augmentation of inflammasome-mediated IL-1ß and IL-6 production by mutant macrophages.","prefix":" in a peripheral blood sample.  ","suffix":"4-7  Complications from COVID-19"}]}]}
>```
>%%
>*%%PREFIX%%in a peripheral blood sample.%%HIGHLIGHT%% ==Clonal hematopoiesis of indeterminate potential (CHIP) is a subtype of clonal hematopoiesis found in individuals without a hematologic malignancy in which a somatic pathogenic mutation in a gene mutated in myeloid neoplasia is present in at least 2% of the sequenced blood DNA (termed variant allele fraction, or VAF).1,2 CHIP is associated with increased mortality and risk of adverse outcomes including cardiovascular and pulmonary disease (COPD).3-5 These associations, which are largely driven by CHIP clones with VAF greater than 0.1, are thought to arise from augmentation of inflammasome-mediated IL-1ß and IL-6 production by mutant macrophages.== %%POSTFIX%%4-7  Complications from COVID-19*
>%%LINK%%[[#^6drr3vmb7gj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6drr3vmb7gj


>%%
>```annotation-json
>{"created":"2022-09-15T02:14:06.996Z","updated":"2022-09-15T02:14:06.996Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":6656,"end":7256},{"type":"TextQuoteSelector","exact":"Complications from COVID-19 are thought to result from an enhanced inflammatory state, potentially mediated by macrophage activation and elevated levels of IL-6, though clinical trials assessing the clinical benefit of IL-6 blockade in patients with COVID-19 have yielded conflicting results.8-16 Clinical risk factors for poor outcomes from COVID-19 include older age, cardiovascular disease, and pulmonary disease.  Given the shared risk factors between CHIP and COVID-19 severity, we examined whether there was an association between CHIP and risk of death in patients hospitalized with COVID-19. ","prefix":"tion by mutant macrophages.4-7  ","suffix":"  The Massachusetts General Brig"}]}]}
>```
>%%
>*%%PREFIX%%tion by mutant macrophages.4-7%%HIGHLIGHT%% ==Complications from COVID-19 are thought to result from an enhanced inflammatory state, potentially mediated by macrophage activation and elevated levels of IL-6, though clinical trials assessing the clinical benefit of IL-6 blockade in patients with COVID-19 have yielded conflicting results.8-16 Clinical risk factors for poor outcomes from COVID-19 include older age, cardiovascular disease, and pulmonary disease.  Given the shared risk factors between CHIP and COVID-19 severity, we examined whether there was an association between CHIP and risk of death in patients hospitalized with COVID-19.== %%POSTFIX%%The Massachusetts General Brig*
>%%LINK%%[[#^pu1hu8lfok|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pu1hu8lfok


>%%
>```annotation-json
>{"created":"2022-09-15T02:14:31.031Z","updated":"2022-09-15T02:14:31.031Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":7770,"end":7913},{"type":"TextQuoteSelector","exact":" Genomic sequencing to identify the presence of CHIP was performed on all samples using either whole genome or targeted as previously described","prefix":"ID-19 (Supplemental Figure 1).10","suffix":" (Supplemental Tables 1-2).18-20"}]}]}
>```
>%%
>*%%PREFIX%%ID-19 (Supplemental Figure 1).10%%HIGHLIGHT%% ==Genomic sequencing to identify the presence of CHIP was performed on all samples using either whole genome or targeted as previously described== %%POSTFIX%%(Supplemental Tables 1-2).18-20*
>%%LINK%%[[#^1sdmtkws9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1sdmtkws9


>%%
>```annotation-json
>{"created":"2022-09-15T02:15:07.586Z","updated":"2022-09-15T02:15:07.586Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":11984,"end":12091},{"type":"TextQuoteSelector","exact":"We did not observe an association between CHIP and risk of dying within 28 days of admission with COVID-19.","prefix":"D and Supplemental Figure 5).   ","suffix":"5,7,9 Our findings are consisten"}]}]}
>```
>%%
>*%%PREFIX%%D and Supplemental Figure 5).%%HIGHLIGHT%% ==We did not observe an association between CHIP and risk of dying within 28 days of admission with COVID-19.== %%POSTFIX%%5,7,9 Our findings are consisten*
>%%LINK%%[[#^96u9leyvcxg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^96u9leyvcxg


>%%
>```annotation-json
>{"created":"2022-09-15T02:15:48.345Z","updated":"2022-09-15T02:15:48.345Z","document":{"title":"blood.2022018052.pdf","link":[{"href":"urn:x-pdf:c149a610f895b358d2bd7c64321cfb62"},{"href":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf"}],"documentFingerprint":"c149a610f895b358d2bd7c64321cfb62"},"uri":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","target":[{"source":"vault:/hematology-theroy/papers/covid19withblood/blood.2022018052.pdf","selector":[{"type":"TextPositionSelector","start":12589,"end":13158},{"type":"TextQuoteSelector","exact":" We also found that the homozygous IL6R D358A SNP A/A, which has been shown to dampen IL-6 signaling, was independently associated with a significantly increased risk of death. Further analysis of primary patient samples and mechanistic work to understand this association is needed.24  A recent study using the UK Biobank found no association between impaired IL-6 signaling and death or need for intubation in patients with COVID-19 but did find an association with increased risk of hospitalization and infection, a question our study was not designed to address.25 ","prefix":"well-established risk modifiers.","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%well-established risk modifiers.%%HIGHLIGHT%% ==We also found that the homozygous IL6R D358A SNP A/A, which has been shown to dampen IL-6 signaling, was independently associated with a significantly increased risk of death. Further analysis of primary patient samples and mechanistic work to understand this association is needed.24  A recent study using the UK Biobank found no association between impaired IL-6 signaling and death or need for intubation in patients with COVID-19 but did find an association with increased risk of hospitalization and infection, a question our study was not designed to address.25== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^n135341r6za|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^n135341r6za
